Horizon Therapeutics [HZNP] vs Pfizer [PFE] Detailed Stock Comparison

Horizon Therapeutics

NASDAQ
Loading...

Pfizer

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Horizon Therapeutics wins in 8 metrics, Pfizer wins in 9 metrics, with 0 ties. Pfizer appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricHorizon TherapeuticsPfizerBetter
P/E Ratio (TTM)61.8613.90Pfizer
Price-to-Book Ratio5.011.68Pfizer
Debt-to-Equity Ratio0.4869.70Horizon Therapeutics
PEG Ratio-16.290.00Horizon Therapeutics
EV/EBITDA24.088.10Pfizer
Profit Margin (TTM)74.64%16.84%Horizon Therapeutics
Operating Margin (TTM)16.83%28.68%Pfizer
EBITDA Margin (TTM)16.83%28.68%Pfizer
Return on Equity10.28%12.17%Pfizer
Return on Assets (TTM)5.72%5.25%Horizon Therapeutics
Free Cash Flow (TTM)N/A$9.84BN/A
Dividend YieldN/A5.32%N/A
1-Year Return-6.82%-13.44%Horizon Therapeutics
Price-to-Sales Ratio (TTM)7.342.35Pfizer
Enterprise Value$26.84B$198.47BPfizer
EV/Revenue Ratio7.403.11Pfizer
Gross Profit Margin (TTM)76.72%74.22%Horizon Therapeutics
Revenue per Share (TTM)$16$11Horizon Therapeutics
Earnings per Share (Diluted)$2.22$1.89Horizon Therapeutics
Beta (Stock Volatility)N/A0.47N/A
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Horizon Therapeutics vs Pfizer Stock Performance Analysis

Loading Price Chart...

Horizon Therapeutics
Pfizer
Horizon Therapeutics Stock Overview | Pfizer Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Horizon Therapeutics0.00%0.00%0.00%0.00%0.00%0.00%
Pfizer-1.71%-6.79%2.14%-1.25%12.23%-5.15%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Horizon Therapeutics-6.82%74.04%9.84%176.66%176.66%176.66%
Pfizer-13.44%-41.11%-29.91%-22.70%49.88%9.41%

News Based Sentiment: Horizon Therapeutics vs Pfizer

Horizon Therapeutics

News sentiment data is not available for Horizon Therapeutics at this time.

Pfizer

News based Sentiment: POSITIVE

October proved to be a pivotal month for Pfizer, marked by a significant drug pricing agreement with the Trump Administration and a better-than-expected Q2 earnings report. These developments, coupled with promising clinical trial data for its obesity drug and strategic AI integration, suggest a positive trajectory for the company and strengthen its long-term investment prospects.

View Pfizer News Sentiment Analysis

Performance & Financial Health Analysis: Horizon Therapeutics vs Pfizer

MetricHZNPPFE
Market Information
Market Cap i$26.63B$146.89B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i19,134,20673,557,650
90 Day Avg. Volume i8,460,69555,325,123
Last Close$116.30$25.24
52 Week Range$116.30 - $116.34$20.92 - $30.43
% from 52W High-0.03%-17.06%
All-Time High$39.49 (Jul 20, 2015)$61.71 (Dec 20, 2021)
% from All-Time High194.50%-59.10%
Growth Metrics
Quarterly Revenue Growth0.14%0.10%
Quarterly Earnings GrowthN/A69.98%
Financial Health
Profit Margin (TTM) i0.75%0.17%
Operating Margin (TTM) i0.17%0.29%
Return on Equity (TTM) i0.10%0.12%
Debt to Equity (MRQ) i0.4869.70
Cash & Liquidity
Book Value per Share (MRQ)$23.22$15.60
Cash per Share (MRQ)N/A$2.33
Operating Cash Flow (TTM) i$1.33B$15.19B
Levered Free Cash Flow (TTM) i$1.81B$16.02B
Dividends
Last 12-Month Dividend Yield iN/A5.32%
Last 12-Month Dividend iN/A$1.27

Valuation & Enterprise Metrics Analysis: Horizon Therapeutics vs Pfizer

MetricHZNPPFE
Price Ratios
P/E Ratio (TTM) i61.8613.90
Forward P/E i20.558.97
PEG Ratio i-16.290.00
Price to Sales (TTM) i7.342.35
Price to Book (MRQ) i5.011.68
Market Capitalization
Market Capitalization i$26.63B$146.89B
Enterprise Value i$26.84B$198.47B
Enterprise Value Metrics
Enterprise to Revenue i7.403.11
Enterprise to EBITDA i24.088.10
Risk & Other Metrics
Beta iN/A0.47
Book Value per Share (MRQ) i$23.22$15.60

Financial Statements Comparison: Horizon Therapeutics vs Pfizer

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)HZNPPFE
Revenue/Sales iN/A$14.65B
Cost of Goods Sold iN/A$3.78B
Gross Profit iN/A$10.88B
Research & Development iN/A$2.48B
Operating Income (EBIT) iN/A$3.77B
EBITDA iN/A$5.75B
Pre-Tax Income iN/A$3.04B
Income Tax iN/A$141.00M
Net Income (Profit) iN/A$2.93B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)HZNPPFE
Cash & Equivalents iN/A$1.43B
Total Current Assets iN/A$45.86B
Total Current Liabilities iN/A$36.45B
Long-Term Debt iN/A$56.82B
Total Shareholders Equity iN/A$90.64B
Retained Earnings iN/A$119.59B
Property, Plant & Equipment iN/AN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)HZNPPFE
Operating Cash Flow iN/A$3.91B
Capital Expenditures iN/A$-564.00M
Free Cash Flow iN/A$1.77B
Debt Repayment iN/A$-2.43B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricHZNPPFE
Shares Short iN/A112.93M
Short Ratio iN/A2.85
Short % of Float iN/A0.02%
Average Daily Volume (10 Day) i19,134,20673,557,650
Average Daily Volume (90 Day) i8,460,69555,325,123
Shares Outstanding i229.00M5.67B
Float Shares iN/A5.68B
% Held by Insiders iN/A0.00%
% Held by Institutions iN/A0.67%

Dividend Analysis & Yield Comparison: Horizon Therapeutics vs Pfizer

MetricHZNPPFE
Last 12-Month Dividend iN/A$1.27
Last 12-Month Dividend Yield iN/A5.32%
3-Year Avg Annual Dividend iN/A$1.52
3-Year Avg Dividend Yield iN/A1.27%
3-Year Total Dividends iN/A$4.55
Ex-Dividend DateN/AJan 24, 2025